Skip to content
Search

Latest Stories

Taapsee Pannu on 6 years of Baby: 7 minutes that changed the direction of tide for me

Taapsee Pannu on 6 years of Baby: 7 minutes that changed the direction of tide for me

By Murtuza Iqbal 

Taapsee Pannu made her Bollywood debut with Chashme Baddoor, but it was her performance in Baby that gave her recognition in the Hindi film industry. It wasn’t a big role, but with just a few scenes, Taapsee had left a mark.


Today, Baby completes six years of its release, so Taapsee tweeted, “Dear actors, Number of minutes don’t matter, the impact u leave with what u do in those minutes ...... matters :) 7 minutes that changed the direction of tide for me FOR GOOD. Yours truly , Naam Shabana @neerajpofficial @ShitalBhatiaFFW @akshaykumar.”

Akshay replied to her tweet, “Absolutely! Always make the most of what you have...proud of you and your onwards and upwards journey :)”

Well, Taapsee’s performance as Shabana Khan had impressed one and all, and that’s why the makers decided on a spin-off titled Naam Shabana which revolved around how she became an agent.

In these six years, Taapsee has featured in some amazing Hindi movies like PINK, Naam Shabana, Mulk, Badla, Mission Mangal, Saand Ki Aankh, and Thappad.

Currently, she is one of the busiest actresses in Bollywood. Taapsee will be seen in movies like Haseen Dillruba, Rashmi Rocket, Looop Lapeta, and Shabaash Mithu. The shooting of Haseen Dillruba has been wrapped up, and currently, the actress is shooting for Rashmi Rocket.

There have been reports of her starring opposite Shah Rukh Khan in Rajkumar Hirani’s next. But there’s no official announcement about it.

A few days ago, while talking to Bollywood Hungama about the movie, Taapsee had stated, “If and when I am doing such a film, I will be the happiest to announce it without being asked.”

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less